Today, ASHP sent a statement to the House Committee on Oversight and Accountability in advance of its hearing on pharmacy benefit manager (PBM) transparency and accountability.
Prior to the hearing, the committee chair, Rep. James Comer (R-KY), released a report noting anticompetitive activity and increased costs to employers and patients caused by PBMs. The committee’s work reinforces the findings of the Federal Trade Commission (FTC) report detailing the impact PBMs have on patient access to medications. Both reports address the concerns ASHP highlighted in its testimony to the FTC.
"Our members have seen firsthand how PBM practices can limit and put at risk patient care," ASHP said in its statement.
ASHP members can learn more about our calls for Congress to pass legislation reforming PBM practices and the findings of the FTC report in this recent blog post from ASHP CEO Paul W. Abramowitz.
